{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:20:29Z","timestamp":1778070029571,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japan Agency for Medical Research and Development (AMED) grant","award":["15 cm0106133h0002"],"award-info":[{"award-number":["15 cm0106133h0002"]}]},{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["grant 17K19591 and 24K12601"],"award-info":[{"award-number":["grant 17K19591 and 24K12601"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04289-5","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:13:20Z","timestamp":1769490800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-5674","authenticated-orcid":false,"given":"Ryusuke","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-0623","authenticated-orcid":false,"given":"Junzo","family":"Hamanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Hosoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rin","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mana","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yamanoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4289_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4289_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10147-024-02473-8","volume":"29","author":"H Nakai","year":"2024","unstructured":"Nakai H, Higashi T, Kakuwa T, Matsumura N (2024) Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021. Int J Clin Oncol 29:363\u2013371. https:\/\/doi.org\/10.1007\/s10147-024-02473-8","journal-title":"Int J Clin Oncol"},{"key":"4289_CR3","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887\u20133895","journal-title":"EMBO J"},{"key":"4289_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515\u2013548. https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115611","journal-title":"Annu Rev Immunol"},{"key":"4289_CR5","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293\u201312297. https:\/\/doi.org\/10.1073\/pnas.192461099","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4289_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","volume":"21","author":"J Hamanishi","year":"2016","unstructured":"Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I (2016) PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 21:462\u2013473. https:\/\/doi.org\/10.1007\/s10147-016-0959-z","journal-title":"Int J Clin Oncol"},{"key":"4289_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","volume":"24","author":"Y Iwai","year":"2017","unstructured":"Iwai Y, Hamanishi J, Chamoto K, Honjo T (2017) Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 24:26. https:\/\/doi.org\/10.1186\/s12929-017-0329-9","journal-title":"J Biomed Sci"},{"key":"4289_CR8","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/jco.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T et al (2015) Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015\u20134022. https:\/\/doi.org\/10.1200\/jco.2015.62.3397","journal-title":"J Clin Oncol"},{"key":"4289_CR9","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/jco.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi J, Takeshima N, Katsumata N et al (2021) Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol 39:3671\u20133681. https:\/\/doi.org\/10.1200\/jco.21.00334","journal-title":"J Clin Oncol"},{"key":"4289_CR10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/s1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA et al (2021) Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol 22:1034\u20131046. https:\/\/doi.org\/10.1016\/s1470-2045(21)00216-3","journal-title":"Lancet Oncol"},{"key":"4289_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/s1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk BJ, Colombo N, Oza AM et al (2021) Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol 22:1275\u20131289. https:\/\/doi.org\/10.1016\/s1470-2045(21)00342-9","journal-title":"Lancet Oncol"},{"key":"4289_CR12","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/jco.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J et al (2021) Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol 39:1842\u20131855. https:\/\/doi.org\/10.1200\/jco.21.00306","journal-title":"J Clin Oncol"},{"key":"4289_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/intimm\/dxw020","volume":"28","author":"J Hamanishi","year":"2016","unstructured":"Hamanishi J, Mandai M, Konishi I (2016) Immune checkpoint inhibition in ovarian cancer. Int Immunol 28:339\u2013348. https:\/\/doi.org\/10.1093\/intimm\/dxw020","journal-title":"Int Immunol"},{"key":"4289_CR14","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/s1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542. https:\/\/doi.org\/10.1016\/s1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"4289_CR15","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1053\/j.seminoncol.2015.09.019","volume":"42","author":"EB Garon","year":"2015","unstructured":"Garon EB (2015) Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol 42(2):S11\u2013S18. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.019","journal-title":"Semin Oncol"},{"key":"4289_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.mct-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.mct-14-0983","journal-title":"Mol Cancer Ther"},{"key":"4289_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Postow MA, Wolchok JD (2016) Targeting T cell co-receptors for cancer therapy. Immunity 44:1069\u20131078. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.023","journal-title":"Immunity"},{"key":"4289_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1078-0432.ccr-12-2063","volume":"19","author":"M Sznol","year":"2013","unstructured":"Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:1021\u20131034. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-2063","journal-title":"Clin Cancer Res"},{"key":"4289_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"key":"4289_CR20","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"4289_CR21","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"key":"4289_CR22","doi-asserted-by":"publisher","first-page":"1862948","DOI":"10.1080\/2162402x.2020.1862948","volume":"10","author":"T Kato","year":"2021","unstructured":"Kato T, Kiyotani K, Tomiyama E et al (2021) Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. Oncoimmunology 10:1862948. https:\/\/doi.org\/10.1080\/2162402x.2020.1862948","journal-title":"Oncoimmunology"},{"key":"4289_CR23","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00262-021-02900-z","volume":"70","author":"Y Nakahara","year":"2021","unstructured":"Nakahara Y, Matsutani T, Igarashi Y et al (2021) Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR\/ALK wild-type NSCLC treated with anti-PD-1 antibody. Cancer Immunol Immunother 70:2881\u20132892. https:\/\/doi.org\/10.1007\/s00262-021-02900-z","journal-title":"Cancer Immunol Immunother"},{"key":"4289_CR24","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","volume":"29","author":"JL Vos","year":"2023","unstructured":"Vos JL, Burman B, Jain S et al (2023) Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nat Med 29:3077\u20133089. https:\/\/doi.org\/10.1038\/s41591-023-02518-x","journal-title":"Nat Med"},{"key":"4289_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/s0171-2985(84)80042-x","volume":"166","author":"AJ Ulmer","year":"1984","unstructured":"Ulmer AJ, Scholz W, Ernst M, Brandt E, Flad HD (1984) Isolation and subfractionation of human peripheral blood mononuclear cells (PBMC) by density gradient centrifugation on Percoll. Immunobiology 166:238\u2013250. https:\/\/doi.org\/10.1016\/s0171-2985(84)80042-x","journal-title":"Immunobiology"},{"key":"4289_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.prp.2015.11.008","volume":"212","author":"N Belder","year":"2016","unstructured":"Belder N, Coskun O, Doganay Erdogan B, Ilk O, Savas B, Ensari A, Ozdag H (2016) From RNA isolation to microarray analysis: comparison of methods in FFPE tissues. Pathol Res Pract 212:678\u2013685. https:\/\/doi.org\/10.1016\/j.prp.2015.11.008","journal-title":"Pathol Res Pract"},{"key":"4289_CR27","doi-asserted-by":"publisher","first-page":"11427","DOI":"10.1038\/s41598-021-91012-w","volume":"11","author":"R Murakami","year":"2021","unstructured":"Murakami R, Hamanishi J, Brown JB et al (2021) Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Sci Rep 11:11427. https:\/\/doi.org\/10.1038\/s41598-021-91012-w","journal-title":"Sci Rep"},{"key":"4289_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2016.02.027","volume":"141","author":"R Murakami","year":"2016","unstructured":"Murakami R, Matsumura N, Brown JB et al (2016) Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecol Oncol 141:49\u201356. https:\/\/doi.org\/10.1016\/j.ygyno.2016.02.027","journal-title":"Gynecol Oncol"},{"key":"4289_CR29","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"4289_CR30","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/s41591-024-03240-y","volume":"30","author":"TJ Alban","year":"2024","unstructured":"Alban TJ, Riaz N, Parthasarathy P et al (2024) Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Nat Med 30:3209\u20133222. https:\/\/doi.org\/10.1038\/s41591-024-03240-y","journal-title":"Nat Med"},{"key":"4289_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fimmu.2013.00413","volume":"4","author":"A Six","year":"2013","unstructured":"Six A, Mariotti-Ferrandiz ME, Chaara W et al (2013) The past, present, and future of immune repertoire biology - the rise of next-generation repertoire analysis. Front Immunol 4:413. https:\/\/doi.org\/10.3389\/fimmu.2013.00413","journal-title":"Front Immunol"},{"key":"4289_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jim.2007.01.019","volume":"321","author":"V Venturi","year":"2007","unstructured":"Venturi V, Kedzierska K, Turner SJ, Doherty PC, Davenport MP (2007) Methods for comparing the diversity of samples of the T cell receptor repertoire. J Immunol Methods 321:182\u2013195. https:\/\/doi.org\/10.1016\/j.jim.2007.01.019","journal-title":"J Immunol Methods"},{"key":"4289_CR33","doi-asserted-by":"publisher","first-page":"R72","DOI":"10.1186\/gb-2011-12-8-r72","volume":"12","author":"D Kim","year":"2011","unstructured":"Kim D, Salzberg SL (2011) TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 12:R72. https:\/\/doi.org\/10.1186\/gb-2011-12-8-r72","journal-title":"Genome Biol"},{"key":"4289_CR34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ajpath.2015.12.029","volume":"186","author":"R Murakami","year":"2016","unstructured":"Murakami R, Matsumura N, Mandai M et al (2016) Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes. Am J Pathol 186:1103\u20131113. https:\/\/doi.org\/10.1016\/j.ajpath.2015.12.029","journal-title":"Am J Pathol"},{"key":"4289_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.it.2014.04.005","volume":"35","author":"JD Galson","year":"2014","unstructured":"Galson JD, Pollard AJ, Truck J, Kelly DF (2014) Studying the antibody repertoire after vaccination: practical applications. Trends Immunol 35:319\u2013331. https:\/\/doi.org\/10.1016\/j.it.2014.04.005","journal-title":"Trends Immunol"},{"key":"4289_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4049\/jimmunol.1301384","volume":"192","author":"C Wang","year":"2014","unstructured":"Wang C, Liu Y, Xu LT et al (2014) Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. J Immunol 192:603\u2013611. https:\/\/doi.org\/10.4049\/jimmunol.1301384","journal-title":"J Immunol"},{"key":"4289_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jim.2016.01.014","volume":"430","author":"SM Theaker","year":"2016","unstructured":"Theaker SM, Rius C, Greenshields-Watson A et al (2016) T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones. J Immunol Methods 430:43\u201350. https:\/\/doi.org\/10.1016\/j.jim.2016.01.014","journal-title":"J Immunol Methods"},{"key":"4289_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033","journal-title":"Cell"},{"key":"4289_CR39","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.Ccr-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585\u20134593. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-3101","journal-title":"Clin Cancer Res"},{"key":"4289_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/po.18.00386","author":"M Offin","year":"2019","unstructured":"Offin M, Guo R, Wu SL et al (2019) Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/po.18.00386","journal-title":"JCO Precis Oncol"},{"key":"4289_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.isci.2019.10.028","volume":"21","author":"Z Wei","year":"2019","unstructured":"Wei Z, Zhou C, Zhang Z, Guan M, Zhang C, Liu Z, Liu Q (2019) The landscape of tumor fusion neoantigens: a pan-cancer analysis. iScience 21:249\u2013260. https:\/\/doi.org\/10.1016\/j.isci.2019.10.028","journal-title":"iScience"},{"key":"4289_CR42","doi-asserted-by":"publisher","first-page":"e1004216","DOI":"10.1371\/journal.pgen.1004216","volume":"10","author":"K Kannan","year":"2014","unstructured":"Kannan K, Coarfa C, Rajapakshe K, Hawkins SM, Matzuk MM, Milosavljevic A, Yen L (2014) CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma. PLoS Genet 10:e1004216. https:\/\/doi.org\/10.1371\/journal.pgen.1004216","journal-title":"PLoS Genet"},{"key":"4289_CR43","doi-asserted-by":"publisher","first-page":"E1272","DOI":"10.1073\/pnas.1501735112","volume":"112","author":"K Kannan","year":"2015","unstructured":"Kannan K, Coarfa C, Chao PW et al (2015) Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma. Proc Natl Acad Sci U S A 112:E1272\u2013E1277. https:\/\/doi.org\/10.1073\/pnas.1501735112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4289_CR44","doi-asserted-by":"publisher","first-page":"46891","DOI":"10.18632\/oncotarget.16781","volume":"8","author":"MA Earp","year":"2017","unstructured":"Earp MA, Raghavan R, Li Q et al (2017) Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. Oncotarget 8:46891\u201346899. https:\/\/doi.org\/10.18632\/oncotarget.16781","journal-title":"Oncotarget"},{"key":"4289_CR45","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.4049\/jimmunol.169.4.1829","volume":"169","author":"JA Coronella","year":"2002","unstructured":"Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169:1829\u20131836. https:\/\/doi.org\/10.4049\/jimmunol.169.4.1829","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04289-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:52:47Z","timestamp":1778068367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04289-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04289-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7492478\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Supplementary files 11 and 12 have been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Kyoto University Graduate School and Faculty of Medicine (approval number: R1000-3 and G531).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"52"}}